

1 **SARS-CoV-2 RNAemia predicts clinical deterioration and extrapulmonary complications**
2 **from COVID-19.**

3
4 Nikhil Ram-Mohan^{*1}, David Kim^{*1}, Elizabeth J Zudock¹, Marjan M Hashemi¹, Kristel C
5 Tjandra¹, Angela J Rogers², Catherine A Blish³, Kari C. Nadeau², Jennifer A Newberry¹, James
6 V Quinn¹, Ruth O'Hara⁴, Euan Ashley⁵, Hien Nguyen⁶, Lingxia Jiang⁶, Paul Hung⁶, the Stanford
7 COVID-19 Biobank Study Group, Andra L Blomkalns¹, Samuel Yang^{1†}

8
9 ¹ Department of Emergency Medicine, Stanford University School of Medicine, Palo Alto CA 94305

10 ² Department of Medicine - Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine,
11 Palo Alto CA 94305

12 ³ Department of Medicine/Infectious Diseases, Stanford University School of Medicine, Palo Alto CA 94305

13 ⁴ Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto CA 94305

14 ⁵ Department of Medicine – Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto CA 94305

15 ⁶ COMBiNATi Inc., 2450 Embarcadero Way, Palo Alto CA 94303

16
17 * Contributed equally

18 † Corresponding author:

19
20 Samuel Yang

21 syang5@stanford.edu

22 (650) 725-9492

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Abstract**

50

51 Background

52 The determinants of COVID-19 disease severity and extrapulmonary complications (EPCs) are
53 poorly understood. We characterise the relationships between SARS-CoV-2 RNAemia and
54 disease severity, clinical deterioration, and specific EPCs.

55

56 Methods

57 We used quantitative (qPCR) and digital (dPCR) PCR to quantify SARS-CoV-2 RNA from
58 nasopharyngeal swabs and plasma in 191 patients presenting to the Emergency Department (ED)
59 with COVID-19. We recorded patient symptoms, laboratory markers, and clinical outcomes,
60 with a focus on oxygen requirements over time. We collected longitudinal plasma samples from
61 a subset of patients. We characterised the role of RNAemia in predicting clinical severity and
62 EPCs using elastic net regression.

63

64 Findings

65 23.0% (44/191) of SARS-CoV-2 positive patients had viral RNA detected in plasma by dPCR,
66 compared to 1.4% (2/147) by qPCR. Most patients with serial measurements had undetectable
67 RNAemia 10 days after onset of symptoms, but took 16 days to reach maximum severity, and
68 33 days for symptoms to resolve. Initially RNAemic patients were more likely to manifest
69 severe disease (OR 6.72 [95% CI, 2.45 – 19.79]), worsening of disease severity (OR 2.43 [95%
70 CI, 1.07 - 5.38]), and EPCs (OR 2.81 [95% CI, 1.26 – 6.36]). RNA load correlated with
71 maximum severity ($r = 0.47$ [95% CI, 0.20 - 0.67]).

72

73 Interpretation

74 dPCR is more sensitive than qPCR for the detection of SARS-CoV-2 RNAemia, which is a
75 robust predictor of eventual COVID-19 severity and oxygen requirements, as well as EPCs.
76 Since many COVID-19 therapies are initiated on the basis of oxygen requirements, RNAemia
77 on presentation might serve to direct early initiation of appropriate therapies for the patients most
78 likely to deteriorate.

79

80 Funding

81 NIH/NIAID (Grants R01A153133, R01AI137272, and 3U19AI057229 – 17W1 COVID SUPP
82 #2) and a donation from Eva Grove.

83

84 Acknowledgements

85 Additional author members of the Stanford COVID-19 Biobank Study Group include: Rosen
86 Mann, Anita Visweswaran, Thanmayi Ranganath, Jonasel Roque, Monali Manohar, Hena Naz
87 Din, Komal Kumar, Kathryn Jee, Brigit Noon, Jill Anderson, Bethany Fay, Donald Schreiber,
88 Nancy Zhao, Rosemary Vergara, Julia McKechnie, Aaron Wilk, Lauren de la Parte, Kathleen
89 Whittle Dantzler, Maureen Ty, Nimish Kathale, Arjun Rustagi, Giovanni Martinez-Colon, Geoff
90 Ivison, Ruoxi Pi, Maddie Lee, Rachel Brewer, Taylor Hollis, Andrea Baird, Michele Ugur, Drina
91 Bogusch, Georgie Nahass, Kazim Haider, Kim Quyen Thi Tran, Laura Simpson, Michal Tal, Iris
92 Chang, Evan Do, Andrea Fernandes, Allie Lee, Neera Ahuja, Theo Snow, James Krempski.

93

94

95 **Research in context**

96

97 Evidence before this study –

98

99 The varied clinical manifestations of COVID-19 have directed attention to the distribution of
100 SARS-CoV-2 in the body. Although most concentrated and tested for in the nasopharynx,
101 SARS-CoV-2 RNA has been found in blood, stool, and numerous tissues, raising questions about
102 dissemination of viral RNA throughout the body, and the role of this process in disease severity
103 and extrapulmonary complications. Recent studies have detected low levels of SARS-CoV-2
104 RNA in blood using either quantitative reverse transcriptase real-time PCR (qPCR) or droplet
105 digital PCR (dPCR), and have associated RNAemia with disease severity and biomarkers of
106 dysregulated immune response.

107

108 Added value of this study –

109

110 We quantified SARS-CoV-2 RNA in the nasopharynx and plasma of patients presenting to the
111 Emergency Department with COVID-19, and found an array-based dPCR platform to be
112 markedly more sensitive than qPCR for detection of SARS-CoV-2 RNA, with a simplified
113 workflow well-suited to clinical adoption. We collected serial plasma samples during patients’
114 course of illness, and showed that SARS-CoV-2 RNAemia peaks early, while clinical condition
115 often continues to worsen. Our findings confirm the association between RNAemia and disease
116 severity, and additionally demonstrate a role for RNAemia in predicting future deterioration and
117 specific extrapulmonary complications.

118

119 Implications of all the available evidence –

120

121 Variation in SARS-CoV-2 RNAemia may help explain disparities in disease severity and
122 extrapulmonary complications from COVID-19. Testing for RNAemia with dPCR early in the
123 course of illness may help guide patient triage and management.

124

125 **Introduction**

126

127 As of December 2020, SARS-CoV-2 has caused over 70 million infections and 1.6 million
128 deaths.¹ The variability of patient responses to COVID-19 makes it difficult for frontline
129 clinicians to identify and appropriately triage patients most at risk for clinical deterioration.
130 While COVID-19 is often manifest as a viral pneumonia, multi-organ involvement can produce
131 more severe and recalcitrant disease.^{2,3} SARS-CoV-2, typically isolated from nasopharyngeal
132 (NP) samples, has been detected in lower titers in whole blood, serum, plasma, and stool.^{4–10}
133 Histopathological surveys have identified the virus in myocardial, renal, gastrointestinal, and
134 neurological tissues.^{11–14} Is haematogenous spread of the virus or viral components associated
135 with extrapulmonary complications (EPCs)? The clinical and pathophysiological significance of
136 SARS-CoV-2 RNA in blood remains poorly understood.

137

138 SARS-CoV-2 RNAemia, detected with quantitative reverse transcriptase real-time PCR
139 (qPCR), has been correlated with severity of COVID-19. However, reported rates of RNA
140 detection range from 0% – 41% in serum and 13% – 33% in plasma.^{4,6,7,10,15–17} Comparing across

141 studies is challenging, due to discrepancies in assay protocols and sensitivities, collections
142 timings, and patient populations. Conventional qPCR also lacks the sensitivity and precision to
143 reliably detect and measure low viral loads.¹⁸ Digital PCR (dPCR) offers improved sensitivity,
144 precision, and reproducibility over qPCR, with absolute quantification of viral RNA without
145 standard curves. Given its tolerance to inhibitors, dPCR is particularly suited to detecting dilute
146 targets in blood.¹⁹ Two cross-sectional studies using droplet-based dPCR reported higher rates of
147 RNAemia (42.4% and 74.1%) than did the qPCR studies above, and associated the presence
148 and the level of RNAemia with clinical severity.^{8,9} Bermejo-Martin *et al* also observed
149 correlation between RNAemia and biomarkers of dysregulated host responses.⁸

150
151 In this prospective, longitudinal, observational study of COVID-19 patients presenting to the
152 Emergency Department (ED), we characterised relationships between SARS-CoV-2 RNAemia
153 and overall severity, clinical deterioration, and specific EPCs. We used an array-based dPCR
154 platform to maximise reliability and replicability, and to simplify potential clinical adoption of
155 RNAemia testing.

156
157 **Materials and Methods**

158
159 COVID-19 patients and specimen collection -

160
161 We collected peripheral blood +/- NP swabs from patients prospectively enrolled in the IRB-
162 approved (eP-55650) Stanford University ED COVID-19 Biobank beginning in April 2020, after
163 written informed consent from patients or their surrogates. Eligibility criteria were age ≥ 18 years
164 and presentation to the Stanford Hospital ED with a positive screening SARS-CoV-2 NP swab,
165 analysed by RT-PCR as part of routine ED care. We repeated blood draws on one or more of
166 days three, seven and 30 if the patient remained hospitalised. We asked discharged participants
167 to return for repeat blood draws on days seven and 30 from enrollment. We collected blood in
168 ethylenediaminetetraacetic acid-chelated vacutainers (Becton, Dickinson, and Co.). We isolated,
169 aliquoted, and stored plasma at -80°C after centrifugation at 1200g for ten minutes at 25°C . We
170 collected NP swabs in 1.5mL of RNA Shield Stabilizing Solution (Zymo Research) and stored
171 solution at -80°C . We performed all sample processing under biosafety level 2+ precautions as
172 approved by Stanford University APB-2551.

173
174 SARS-CoV-2 RNA extraction -

175
176 We extracted RNA from research NP swab and plasma using the QIAamp Viral RNA Mini Kit
177 and QIAcube Connect (QIAGEN). We used 140 μL of NP swab suspension or plasma as input
178 and eluted RNA in 50 μL of elution buffer after lysing for 10 minutes before transferring to
179 QIAcube connect.

180
181 SARS-CoV-2 RNA detection and quantification -

182
183 Multiplexed qPCR and dPCR reactions included the extracted RNA, |Q| Triplex Assay
184 (Combinati), and 4x RT-dPCR MM (Combinati). The |Q| Triplex Assay (Combinati) included
185 primers and probes targeting the N1 and N2 regions of the nucleoprotein gene and the human
186 ribonuclease P gene (RP). We divided the reaction mixture as follows: 10 μL for qPCR using the

187 QuantStudio 5 (Applied Biosystems by Thermo Fisher Scientific) and 9 μ L for dPCR using the
188 array based |Q| (Combinati) (Web Extra Material). Every qPCR and dPCR run included a non-
189 template control (NTC) extracted using the QIAcube (NTC-QIA), NTC for PCR, positive
190 extraction control using a combination of the SARS-CoV-2 Specimen positive and negative
191 recombinants (Zeptomatrix Corporation), and a positive PCR control with the SARS-CoV-2
192 Standard from Exact Diagnostics.

193
194 We considered a qPCR specimen to be positive if cycle threshold (Ct) for RP, N1, and N2 were
195 all less than 40. For positive samples, we used the lesser (i.e., more readily detected) of N1/N2
196 Ct for quantitative analysis. We repeated qPCR if the Ct value for RP was greater than 40. We
197 defined a dPCR sample as positive if both N1 and N2 were detected at concentrations of at least
198 0.23 copies/ μ L, and used the larger of the two concentrations for quantitative analysis. We set
199 negative qPCR results to 40 (our Ct threshold), and negative dPCR results to zero. We calculated
200 pairwise Pearson's correlations between measures of qPCR Ct and log-transformed RNA
201 concentrations from dPCR.

202
203 Patients with specimens collected on days after enrollment (day zero) typically had specimens
204 collected on day three or seven, not both. Thus, we combined days three and seven (hereafter day
205 3/7) for purposes of sequential analyses. For patients who had the same test performed on both
206 days, we used the greater of the two values.

207
208 Clinical and laboratory measures -
209

210 For all participants, we recorded clinical severity of COVID-19 on enrollment and at the time of
211 every additional blood draw, and noted the maximum severity attributable to COVID-19 for 30
212 days after each patient's enrollment, using a World Health Organization (WHO) COVID-19
213 severity scale modified for our institution's COVID-19 oxygenation protocols: 1 = asymptomatic
214 infection not requiring admission, 2 = symptomatic infection not requiring admission, 3 =
215 admitted without supplemental oxygen, 4 = admitted, requiring oxygen by nasal cannula, 5 =
216 admitted, requiring oxygen by high-flow nasal cannula, 6 = admitted, requiring mechanical
217 ventilation, 7 = admitted, requiring mechanical ventilation *and* vasopressors or renal replacement
218 therapy, 8 = death from COVID-related cause.²⁰ We also clustered scores as mild (1-2),
219 moderate (3-4), and severe (5-8). We observed dates associated with initial and maximum WHO
220 severity scores, and each participant's diagnoses at the time of discharge.

221
222 For each participant, we recorded demographic features (age, sex, Hispanic ethnicity),
223 comorbidities (lung disease, cancer, diabetes, immunosuppression, heart disease, hypertension,
224 angiotensin converting enzyme inhibitor [ACE-I] or angiotensin receptor blocker [ARB] use,
225 stroke, dementia, deep venous thrombosis or pulmonary embolus [DVT/PE], chronic kidney
226 disease [CKD], tobacco smoking), initial ED vital signs (systolic [SBP], diastolic [DBP], and
227 mean arterial pressure [MAP], heart rate [HR], respiratory rate [RR], oxygen saturation by pulse
228 oximetry [SpO₂], temperature), presence of pneumonia on chest X-ray or computed tomography,
229 patient-reported symptoms (fever, chills, cough, sore throat, congestion, shortness of breath,
230 chest pain, myalgias, nausea, vomiting, diarrhea, loss of taste, loss of smell, confusion,
231 headache), and laboratory values (leukocyte count, absolute lymphocyte count, haemoglobin,
232 platelet count, D-dimer, fibrinogen, prothrombin time [PT], partial thromboplastin time [PTT],

233 erythrocyte sedimentation rate [ESR], C-related peptide [CRP], procalcitonin, lactate
234 dehydrogenase [LDH], ferritin, troponin, lactate, sodium, potassium, chloride, bicarbonate, blood
235 urea nitrogen [BUN], creatinine, calcium, magnesium, glucose, bilirubin, aspartate
236 aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase).

237
238 We dichotomised vital signs as follows: MAP was low if below 88mmHg (the 25th percentile for
239 enrolled patients), high if above 140mmHg (75th percentile). We did not use a typical clinical
240 definition of hypotension such as MAP below 65mmHg because no patients met this threshold at
241 the time of study enrollment. RR was low if less than 8, high if greater than 20. SpO₂ was low if
242 less than 95% (the 25th percentile). Temperature was high if 38°C or greater, low if less than
243 36°C. We dichotomised laboratory values (high or low) based on our laboratory's normal ranges.
244 For the purpose of predictive models, missing dichotomised laboratory values were imputed
245 nonparametrically for each participant with a Random Forests model, using 100 trees, and 10
246 iterations (R package *missForest* version 1.4).

247
248 Defining extrapulmonary complications -

249
250 We created binary indicators for whether each participant had any of six EPCs during their
251 encounter. Patients were considered to have *neurologic* involvement if they were diagnosed with
252 one or more of: acute stroke, encephalitis, meningitis, neuroinflammatory disease, delirium.
253 *Cardiovascular* involvement included myocardial injury, acute coronary syndrome,
254 cardiomyopathy, acute cor pulmonale, arrhythmia, or cardiogenic shock. *Renal* involvement was
255 defined by acute kidney injury. Transaminitis or hyperbilirubinemia constituted *hepatobiliary*
256 involvement. *Hematologic* involvement included deep vein thrombosis, pulmonary embolus,
257 myocardial infarction, acute stroke, acute limb ischemia, mesenteric ischemia, or catheter-related
258 thrombosis. Patients were considered to have *immunologic* involvement if they received a
259 diagnosis of sepsis, septic shock, multi-organ failure, or secondary bacterial infection.

260
261 Characterising associations between RNAemia and clinical severity -

262
263 We calculated mean maximum WHO severity scores for patients who were initially RNAemic
264 and non-RNAemic, and compared mean scores with a two-sample t-test. Among RNAemic
265 patients, we calculated Pearson's correlation between log-transformed concentration of RNA in
266 plasma, and maximal clinical severity (WHO 1-8). We calculated proportions of RNAemic and
267 non-RNAemic patients who manifested mild (WHO 1-2), moderate (WHO 3-4), and severe
268 (WHO 5-8) disease, who were admitted to the hospital, who manifested EPCs, and who
269 worsened after presentation (i.e., had a maximum WHO score exceeding WHO score at
270 enrollment). We compared the proportions of RNAemic and non-RNAemic patients in each of
271 those categories using chi-squared tests with continuity corrections. We calculated the odds ratio
272 for clinical deterioration, by RNAemia on enrollment (using the odds ratio for consistency with
273 logistic regression results), and calculated exact 95% confidence intervals.²¹ We compared
274 median length-of-hospitalisation in days, and median degree of clinical worsening (difference
275 between initial and maximum WHO score), for RNAemic and non-RNAemic patients, using
276 the Wilcoxon rank-sum test with continuity correction to compare these distributions.

277
278 Predictive models for severe disease, extrapulmonary complications, and RNAemia -

279
280 We developed a predictive model for severe (WHO 5-8) disease, based on data available upon
281 patient presentation. We included the following variables as potential predictors of severe
282 disease: demographic features, comorbidities, binary indicators of abnormal ED vital signs,
283 pneumonia on chest X-ray or CT, patient-reported symptoms, and binary indicators of abnormal
284 lab values (described above). Because therapies such as Remdesivir and dexamethasone were
285 generally initiated after ED presentation, and on the basis of oxygen requirements (the main
286 constituent of the WHO severity score), we did not include specific treatments in our predictive
287 models.

288
289 To prevent overfitting, given a large number of potential predictors compared to the number of
290 patients, we selected variables via elastic net regularisation (*glmnet* 4.0 in R), using logistic
291 models and 10-fold cross-validation, selecting the regularisation parameter λ minimising mean
292 cross-validated error. We then used the selected variables in a logistic model, and estimated odds
293 ratios and 95% confidence intervals for prediction of severe disease, for each of the selected
294 features. We calculated mean cross-validated area under the receiver-operating characteristic
295 curve (AUROC) of the resulting model.

296
297 We predicted the presence of EPCs in analogous fashion, excluding the patient-reported
298 symptoms potentially constitutive of EPCs as defined above, and excluding laboratory markers,
299 many of which were used in definition of EPCs. We again selected variables via cross-validated
300 elastic-net regularisation, estimated odds ratios for the most robust predictors of EPCs, and
301 characterised overall predictive accuracy by AUROC.

302
303 Finally, we predicted the presence of RNAemia in analogous fashion, using as potential
304 predictors demographic features, comorbidities, and symptoms, but excluding radiographic and
305 laboratory findings.

306 307 **Results**

308
309 Patient characteristics on enrollment -

310
311 We enrolled 191 COVID-19 positive ED patients, all of whom had plasma sampled on day of
312 enrollment (day zero). Some patients had additional NP or plasma samples collected at one or
313 more of days: three, seven, 30. 49.2% (94/191) of participants were women. Median age was 47
314 years (IQR 34 - 61). Patients had a median of one comorbidity (IQR 0-3) from the following list:
315 lung disease, cancer, diabetes, immunosuppression, heart disease, hypertension, ACE-I/ARB use,
316 stroke, dementia, DVT/PE, CKD. Patients reported a median of four (IQR 2-6) symptoms from
317 the following list: fever, chills, cough, sore throat, congestion, shortness of breath, chest pain,
318 myalgia, nausea/vomiting/diarrhea (any), loss of taste, loss of smell, confusion, headache. Patient
319 characteristics at enrollment are summarised in Table 1.

320
321 SARS-CoV-2 RNA prevalence by sample type, method, and day of collection -

322
323 dPCR was more sensitive than qPCR for the detection of RNAemia, detecting RNAemia in
324 23.0% (44/191) of patients on day zero, compared to 1.4% (2/147) for qPCR. On day three,

325 dPCR detected RNAemia in 13.3% (6/45) of specimens, compared to zero for qPCR. On day
326 seven, dPCR detected RNAemia in 6.8% (3/44), compared to zero for qPCR. At day 30, neither
327 dPCR nor qPCR detected RNAemia in the 32 specimens tested. We describe the analytical
328 performance of the dPCR assay in the Web Extra Material.

329
330 We observed a modest negative correlation ($r = -0.30$) between qPCR Ct values and dPCR RNA
331 concentrations for the same plasma specimens (Figure 1). Notably, the correlation between NP
332 and plasma dPCR values across 48 paired specimens was very weak ($r = 0.16$). Plasma RNA by
333 dPCR on day zero was moderately correlated with the same measure on day 3/7 ($r = 0.42$).

334
335 Persistence of RNAemia -
336

337 We classified the maximum clinical severity for each enrolled patient as mild (54), moderate
338 (104), or severe (33) (Figure 2). Of the 44 patients RNAemic by dPCR on day zero, 27 had
339 additional draws on days three, seven, or 30. Of these, 92.6% (25/27) had highest RNA on day
340 zero, 22.2% (6/27) were persistently RNAemic at day 3/7, and 7.4% (2/27) had rising RNA by
341 day 3/7 after enrollment. 50 patients with positive screening swabs who were not RNAemic on
342 day zero had plasma drawn again on day 3/7. Of these, only 2.0% (1/50) became RNAemic on
343 day 3/7.

344
345 RNAemia and severity of disease -
346

347 RNAemic patients had higher mean clinical severity (4.80) than non-RNAemic patients (3.24,
348 difference = 1.56 [95% CI, 1.00 - 2.11]). 40.9% of RNAemic patients developed severe disease,
349 compared to 10.2% of non-RNAemic patients (difference = 30.7% [95% CI of difference,
350 13.9% - 47.5%]). Conversely, 4.5% of initially RNAemic patients had mild disease, compared
351 to 35.4% of non-RNAemic patients (difference = 30.8% [95% CI of difference, 19.5% -
352 42.2%]) (Figure 3A). Among patients with detectable RNAemia at time of enrollment ($n=44$),
353 patients with higher plasma RNA concentrations manifested more severe disease ($r = 0.47$ [95%
354 CI, 0.20 - 0.67]) (Figure 3B). Severity trended higher in persistently RNAemic patients,
355 compared to patients RNAemic at day zero but not at day 3/7 (mean WHO score 6.5 vs 5.0), but
356 the difference was not significant (95% CI of difference, -0.58 - 3.58).

357
358 90.9% (40/44) of RNAemic patients, and 70.1% (103/147) of non-RNAemic patients required
359 hospital admission (difference = 20.8% [95% CI, 8.1% - 33.6%]). Among admitted patients,
360 RNAemic patients had longer median length-of-stay (7.6 vs 5.1 days, $p < 0.01$, Wilcoxon rank-
361 sum test with continuity correction).

362
363 In an elastic-net regularised, cross-validated logistic model of severe (WHO 5-8) disease, the
364 significant predictors of severe disease were tobacco smoking, low SpO2 on ED arrival, and
365 RNAemia (OR of RNAemia for severe disease = 6.72 [95% CI, 2.45 - 19.79]). The overall
366 predictive performance of the model was good, with mean cross-validated AUROC of 0.82
367 (Table 2).

368
369 Dynamics of infection through course of illness—
370

371 27 patients had RNAemia at enrollment and one or more subsequent plasma samples. A
372 majority (14/27) of these patients had undetectable RNAemia by day ten from symptom onset,
373 while the same proportion took 16 days to reach maximum severity, and 33 days until resolution
374 of symptoms (Figure 4). Of these 27 patients, 2 had mild disease at enrollment, 20 had moderate
375 disease, and 5 had severe disease. Through the disease course, 17 improved to mild severity, six
376 remained severe, and three died in the hospital.

377
378 In the total study population (i.e., not restricted to those with serial plasma samples), 77.0%
379 (147/191) of patients manifested their maximum clinical severity on the day of study enrollment
380 (i.e., when patients presented to the ED), while 23.0% (44/191) worsened 24 hours or more after
381 enrollment (Figure 5). 36.4% (16/44) of initially RNAemic patients, and 19.0% (28/147) of
382 non-RNAemic patients worsened in severity after initial presentation (difference = 17.4% [95%
383 CI of difference, 0.3% - 34.4%], OR 2.43 [95% CI, 1.07 - 5.38]). RNAemic patients worsened
384 by a median of three points on the modified WHO scale, compared to one point for non-
385 RNAemic patients ($p = 0.02$, Wilcoxon rank-sum test with continuity correction).

386
387 RNAemia predicts extrapulmonary complications -

388
389 56.8% (25/44) of RNAemic patients developed one or more extrapulmonary complications,
390 compared to 30.6% (45/147) those non-RNAemic (difference in proportions = 26.2% [95% CI,
391 8.3% - 44.1%]) (Figure 6). RNAemic patients tended toward higher rates of EPCs across
392 systems, though only differences in rates of hepatobiliary, haematologic, and immunologic
393 complications were individually statistically significant at $p < 0.05$ (chi-squared tests for equality
394 of proportions with continuity correction).

395
396 In an elastic-net regularised, cross-validated logistic model, significant predictors that a patient
397 would manifest one or more EPCs were: chronic kidney disease, obesity, and RNAemia (OR
398 2.81 [95% CI, 1.26 - 6.36]). The overall predictive performance of the model was fair, with
399 mean cross-validated AUROC of 0.73 (Table 3).

400
401 Prediction of RNAemia on presentation -

402
403 We sought to determine whether the patients with RNAemia on presentation could be predicted
404 on the basis of their demographics, comorbidities, symptoms, and ED vital signs. In an
405 analogous regularised, cross-validated logistic model (Table S1), significant predictors of
406 RNAemia on presentation were limited to cough and hypoxia, though the overall predictive
407 performance of the model was poor (mean cross-validated AUROC 0.66).

408
409 **Discussion**

410
411 The pathogenesis of COVID-19, its temporal dynamics, and the determinants of disease severity
412 and extrapulmonary complications are incompletely understood. We explored the performance
413 and clinical utility of dPCR in quantifying SARS-CoV-2 RNA in the nasopharynx and plasma,
414 and characterised the relationships between RNAemia and disease severity, clinical
415 deterioration, and extrapulmonary complications. Array-based dPCR was much more sensitive
416 than qPCR for the detection of SARS-CoV-2 in plasma, where mean concentration of viral RNA

417 was three orders of magnitude less than in the nasopharynx. RNAemia manifests early in the
418 course of illness, while clinical manifestations peak later and are more prolonged. RNAemia at
419 presentation predicts severe disease, ongoing clinical deterioration, and specific extrapulmonary
420 complications.

421
422 We found dPCR to be markedly more sensitive than qPCR even while using more stringent
423 detection criteria (both N1 and N2 ≥ 0.23 copies/ μ L) than other studies (e.g., either N1 or N2
424 ≥ 0.1 copies/ μ L).⁸ dPCR was also more consistent in multiplex detection of both regions (N1
425 and N2) of the SARS-CoV-2 nucleocapsid gene, likely related to the partition format in dPCR
426 reducing preferential amplifications often observed in bulk PCR.²² Moreover, a dPCR platform
427 based on microwell array enhances partition consistency, minimises dead volume for improved
428 sensitivity, and has a workflow identical to qPCR, making it suitable for incorporation into
429 existing clinical workflows. Early in the course of an outbreak, before viral RNA standard curves
430 are widely available, dPCR is a natural choice for detecting a novel pathogen.

431
432 RNAemia on presentation was a major predictor of both severe disease and extrapulmonary
433 complications, after accounting for demographics, comorbidities, symptoms, vital signs, and a
434 host of laboratory markers. Moreover, RNAemic patients were more likely than non-RNAemic
435 patients to worsen after presentation, and RNAemic patients who worsened did so by a greater
436 degree. Previous studies have associated RNAemia with disease severity and mortality.^{8,10,23}
437 Reported associations between RNAemia and extrapulmonary involvement are more
438 varied.^{2,24,25} In addition to characterising the temporal dynamics of clinical deterioration, we
439 included a more comprehensive scope of potential confounders than previous studies.⁸ We also
440 use cross-validation not only for model selection, but to assess the relative predictability of
441 clinical severity (good, AUROC 0.82), extrapulmonary complications (fair, AUROC 0.73), and
442 RNAemia itself (poor, AUROC 0.66). The poor predictability of RNAemia from patient
443 features observable on initial presentation, and the weak correlations between NP and plasma
444 measurements of SARS-CoV-2 RNA, suggest that RNAemia is not simply a consequence of
445 sufficient viral load at the typical site of inoculation, but may instead signal unique
446 pathophysiologic and prognostic features.^{6,26,27}

447
448 SARS-CoV-2 RNAemia might arise from spillage from the respiratory tract, or from active
449 viral replication in vascular endothelial or perivascular cells.^{28,29} Whether RNAemia represents
450 intact, replicating virus cannot be directly determined from our data, and an attempt to culture
451 SARS-CoV-2 from serum with low RNA levels was not successful.³⁰ SARS-CoV-1, however,
452 has been found to replicate in circulating lymphocytes, monocytes, macrophages, and dendritic
453 cells.³¹⁻³³ The RNAemia kinetics we observed follow a typical viral kinetic pattern, with high
454 peak viral load early in the infection, followed by rapid decay (likely reflecting the innate
455 immune response), before a slower clearance (from acquired immunity).³⁴ RNAemia prior to
456 symptom onset has been anecdotally reported; more data is needed to better assess potential pre-
457 symptomatic dynamics.³⁰ Since our findings suggest that RNAemia on presentation reflects the
458 likelihood of subsequent disease progression, early testing for RNAemia could prove useful for
459 the targeted initiation and monitoring of antiviral therapies.³⁴

460
461 The association we observed between RNAemia and EPCs (which we defined conservatively
462 based on diagnoses at discharge, rather than surrogate biomarkers alone), is stronger than in

463 some previous reports.²⁵ Extrapulmonary injury could result from direct viral toxicity,
464 endothelial cell damage and thromboinflammation, dysregulation of the immune response, or
465 dysregulation of the renin–angiotensin–aldosterone system.² Transaminitis, a common
466 hepatobiliary complication we observed in RNAaemic patients, might result from direct
467 hepatocellular injury by SARS-CoV-2, from cytokine storm and hypoxia-associated metabolic
468 derangement, or from drug-induced liver injury (particularly secondary to investigational agents
469 such as remdesivir, lopinavir, and tocilizumab). The trend we observed toward higher incidence
470 of acute kidney injury in RNAaemic patients is consistent with prior evidence for renal
471 tropism.¹²

472
473 We found that SARS-CoV-2 RNAaemia at the time of initial ED presentation is a robust
474 predictor of patients' eventual clinical severity and EPCs. Despite the limited generalisability of
475 our single centre study, the substantial predictive value of RNAaemia in multiple aspects of the
476 disease course suggests a role for plasma dPCR in triage and disposition. Since we use a measure
477 of severity based primarily on oxygen requirements (i.e., the modified WHO score), and since
478 many COVID-19 therapies are initiated on the basis of oxygen requirements, RNAaemia on
479 presentation might serve to direct early initiation of appropriate therapies for the patients most
480 likely to deteriorate.

481

482 **Contributors**

483
484 SY conceived the study. SY, AJR, CAB, KN, ALB, RO, EA, JAN, JVQ established the Stanford
485 COVID-19 Biobank. EJZ enrolled patients and compiled clinical data. NR, MMH, KT, HN, LJ,
486 PH collected and processed the PCR data. DK did the modelling and statistical analysis. NR and
487 DK did the longitudinal analysis. DK and NR drafted the manuscript and produced the figures.
488 All authors contributed to writing the manuscript and approved the final version.

489

490 **Declaration of interests**

491

492 SY is a Scientific Advisory Board member of COMBiNATi Inc.

493

494 **Data sharing**

495

496 De-identified study data are presented as online datasets.

497

498

499

500

501

502

503

504

505

506


507

508

509
510
511
512
513
514


Figures

515



516
517
518
519
520
521
522
523
524

Figure 1. Pairwise Pearson's correlations between measures of nasopharyngeal (NP) and plasma SARS-CoV-2 RNA load. Colors reflect absolute pairwise correlation, as qPCR cycle thresholds are expected to be inversely proportional to SARS-CoV-2 RNA concentrations as measured by dPCR. Plasma RNA concentration by dPCR at enrollment ("Plasma dPCR day 0") is modestly negatively correlated ($r = -0.30$) with qPCR Ct on the same specimen, moderately correlated with plasma dPCR on day 3/7 ($r = 0.42$), and poorly correlated with RNA concentration in the nasopharynx ($r = 0.16$), suggesting that RNAemia is weakly related to nasopharyngeal viral load. NP = nasopharyngeal swab. qPCR = quantitative PCR. dPCR = digital PCR.




525

526

527

528 **Figure 2. Distribution of discrete and binned WHO severity scores.** We classified the maximum severity of 147
529 SARS-CoV-2 presentations using a modified WHO score, as follows: 1 = asymptomatic infection, 2 = symptomatic
530 infection not requiring admission, 3 = admitted without supplemental oxygen, 4 = admitted, requiring oxygen by
531 nasal cannula, 5 = admitted, requiring oxygen by high-flow nasal cannula, 6 = admitted, requiring mechanical
532 ventilation, 7 = admitted, requiring mechanical ventilation and vasopressors or renal replacement therapy, 8 = death
533 from COVID-related cause. **A.** Distribution of WHO scores. **B.** Distribution of binned (mild, moderate, severe)
534 scores.

535




536

537


538

539 **Figure 3. SARS-CoV-2 RNAemia and clinical severity.** **A.** RNAemic patients had higher mean maximum
540 WHO scores (4.80) than non-RNAemic patients (3.24, difference = 1.56 [95% CI of difference, 1.00 - 2.11]).
541 40.9% of RNAemic patients developed severe disease, compared to 10.2% of non-RNAemic patients (difference
542 = 30.7% [95% CI of difference, 13.9% - 47.5%]). 4.5% of initially RNAemic patients had mild disease, compared
543 to 35.4% of non-RNAemic patients (difference = 30.8% [95% CI of difference, 19.5% - 42.2%]). The same
544 proportion (54.5%) of both RNAemic and non-RNAemic patients had disease of moderate severity. **B.** Among
545 patients with detectable RNAemia at time of enrollment (n=44), patients with higher plasma RNA concentrations
546 manifested more severe disease ($r = 0.47$ [95% CI, 0.20 - 0.67]). RNA concentrations in RNAemic patients were
547 distributed approximately log-normally, so were log-scaled for depiction and calculation of correlation. Dashed blue
548 line shows linear correlation between log-scaled plasma RNA concentration and maximum clinical severity.




549
550 **Figure 4. Dynamics of SARS-CoV-2 RNAemia and clinical severity, by modified WHO score. A.** Serial
551 plasma SARS-CoV-2 RNA concentrations and WHO scores for each of the 27 patients with longitudinal samples.
552 Plasma RNA concentration (red gradient) and WHO scores (blue gradient) are shown with respect to the number of
553 days since the reported onset of symptoms (not date of study enrollment) for each patient. Patients who died in the
554 hospital are highlighted in bold and italics. Specimens with undetectable RNAemia are represented as \square . Most
555 (14/27) patients had undetectable RNAemia by day 10, while the same proportion took 16 days to reach maximum
556 severity, and 33 days for resolution of symptoms. **B.** Aggregate RNA and clinical dynamics in the 30 days following
557 onset of symptoms. Loess regression curves represent trends in RNA and clinical dynamics. RNAemia peaked 3
558 days after symptom onset, while clinical severity peaked at 14 days.
559
560

561



562
563
564
565
566
567
568
569
570
571

Figure 5. Trajectories of patient severity, by RNAemia on initial presentation. 36.4% (16/44) of initially RNAemic patients, and 19.0% (28/147) of non-RNAemic patients worsened in severity after initial presentation (difference = 17.4% [95% CI of difference, 0.3% - 34.4%]). RNAemic patients worsened by a median of three points on the modified WHO scale, compared to one point for non-RNAemic patients ($p = 0.02$, Wilcoxon rank-sum test with continuity correction). Day zero represents day of patient enrollment. Values prior to day zero are based on patient's first reported day of symptoms. Values after day zero are based on the date of each patient's maximum WHO score. Red trajectories are those that increase in severity after presentation, by modified WHO score.



572
573
574
575
576
577
578
579
580
581
582
583
584

Figure 6. Presence of extrapulmonary complications, by RNAemia. 56.8% (25/44) of patients RNAemic on enrollment patients developed one or more extrapulmonary complications by hospital discharge, compared to 30.6% (45/147) of non-RNAemic patients (difference in proportions = 26.2% [95% CI, 8.3% - 44.1%]). RNAemic patients tended toward higher rates of extrapulmonary complications across systems, though only differences in rates of hepatobiliary (HB), haematologic, and immunologic complications were individually statistically significant at $p < 0.05$ (chi-squared tests for equality of proportions with continuity correction). *CV* = cardiovascular, *HB* = hepatobiliary.

585 **Tables**

586

587 **Table 1. Patient characteristics on enrollment.**

588

Characteristic	Value
N	191
Female	49.2% (94/191)
Median age (IQR)	47 (IQR 34 - 61)
Medical history:	
Lung disease	12.6% (24/191)
Cancer	13.6% (26/191)
Diabetes	26.7% (51/191)
Immunosuppression	7.3% (14/191)
Heart disease	11.0% (21/191)
Hypertension	36.6% (70/191)
ACE/ARB use	18.3% (35/191)
Stroke	4.2% (8/191)
Dementia	4.7% (9/191)
DVT/PE	5.8% (11/191)
Chronic kidney disease	9.9% (19/191)
Smoking	20.9% (40/191)
Symptoms on presentation:	
Fever	64.4% (123/191)
Chills	31.4% (60/191)
Cough	67.5% (129/191)
Sore throat	16.2% (31/191)
Congestion	8.4% (16/191)
Shortness of breath	63.4% (121/191)
Chest pain	34.6% (66/191)
Myalgia	34.6% (66/191)
Nausea/vomiting/diarrhea	40.8% (78/191)
Loss of taste	38.7% (74/191)
Loss of smell	27.2% (52/191)
Confusion	2.6% (5/191)
Headache	26.2% (50/191)

589

590 ACE = Angiotensin-converting enzyme inhibitor, ARB = Angiotensin receptor blocker, DVT = deep vein
591 thrombosis, PE = pulmonary embolus.

592 **Table 2. Prediction of severe disease.**
593

	OR (95% CI)
PMH: DM	1.51 (0.51 - 4.45)
Smoker	3.13 (1.08 - 9.38)
ED: MAP low	2.59 (0.92 - 7.47)
ED: SpO2 low	5.36 (2.03 - 15.07)
ALC low	3.12 (1.00 - 9.8)
Lactate high	3.90 (0.63 - 22.91)
Glucose high	2.58 (0.92 - 7.30)
RNAemic	6.72 (2.45 - 19.79)
N	191
AIC	134.74
AUROC	0.82

594
595
596 Potential predictors of severe (WHO 5-8) disease included: demographic features (age 60+ or 80+, sex), past
597 medical history features (lung disease, cancer, diabetes, immunosuppression, heart disease, hypertension,
598 angiotensin converting enzyme inhibitor or angiotensin receptor blocker use, stroke, dementia, deep venous
599 thrombosis or pulmonary embolus, chronic kidney disease, tobacco smoking, obesity), binary indicators of abnormal
600 ED vital signs (low or high mean arterial pressure, low or high heart rate, low or high respiratory rate, low oxygen
601 saturation, low or high temperature), pneumonia on chest X-ray or CT, patient-reported symptoms (fever, chills,
602 cough, sore throat, congestion, shortness of breath, chest pain, myalgias, nausea/vomiting/diarrhea, loss of taste, loss
603 of smell, confusion, headache), and binary indicators of abnormal lab values (high or low leukocyte count, low
604 absolute lymphocyte count, low haemoglobin, low or high platelet count, high D-dimer level, high fibrinogen level,
605 low fibrinogen level, high prothrombin time, high partial thromboplastin time, high C-related peptide level, high
606 lactate dehydrogenase level, high ferritin level, high troponin level, high lactate level, high or low sodium level, high
607 or low potassium level, high or low chloride level, high or low bicarbonate level, high blood urea nitrogen level,
608 high creatinine level, high or low calcium level, high or low magnesium level, high or low glucose level, high
609 bilirubin level, high aspartate aminotransferase level, high alanine aminotransferase level, high alkaline phosphatase
610 level).

611 To prevent over-fitting, predictors were selected via elastic net regression of severe disease on these
612 features with 10-fold cross-validation, selecting the regularisation parameter λ minimizing mean cross-validated
613 error, and yielding the features in the table above. In a logistic model regressing severe disease on these features,
614 significant predictors of severe disease included: tobacco smoking, low oxygen saturation (SpO2), and RNAemia.
615 RNAemia was associated with 6.7 times the odds of severe disease, adjusting for other features selected by elastic
616 net penalised regression, an association comparable in magnitude to the association of hypoxia on initial
617 presentation with eventual severe disease. Mean cross-validated area under the receiver-operating characteristic
618 curve (AUROC) of the model in predicting severe disease was 0.82.
619

620 **Table 3. Prediction of extrapulmonary complications.**
621

	OR (95% CI)
Age: 80+	2.27 (0.49 - 9.92)
PMH: Heart	2.13 (0.63 - 7.41)
PMH: HTN	1.74 (0.81 - 3.69)
PMH: Dementia	3.60 (0.58 - 25.33)
PMH: CKD	4.56 (1.36 - 17.27)
Smoker	1.88 (0.80 - 4.42)
Obese	2.64 (1.23 - 5.84)
ED: RR high	1.63 (0.79 - 3.35)
ED: SpO2 low	1.34 (0.60 - 2.93)
RNAemic	2.81 (1.26 - 6.36)
N	191
AIC	222.25
AUROC	0.73

622
623 Potential predictors of extrapulmonary complications (EPCs) included: demographic features (age 60+ or 80+, sex),
624 past medical history features (lung disease, cancer, diabetes, immunosuppression, heart disease, hypertension,
625 angiotensin converting enzyme inhibitor or angiotensin receptor blocker use, stroke, dementia, deep venous
626 thrombosis or pulmonary embolus, chronic kidney disease, tobacco smoking, obesity), binary indicators of abnormal
627 ED vital signs (low or high mean arterial pressure, low or high heart rate, low or high respiratory rate, low oxygen
628 saturation, low or high temperature), pneumonia on initial chest X-ray or CT, and patient-reported symptoms on
629 enrollment excluding those constitutive of extrapulmonary diagnosis (fever, chills, cough, sore throat, congestion,
630 shortness of breath, chest pain, myalgias). Laboratory values were not included as many were constitutive of
631 extrapulmonary diagnoses.

632 To prevent over-fitting, predictors were selected via elastic net regression of EPC (1 if a patient had one or
633 more EPC, 0 if none) on these features with 10-fold cross-validation, selecting the regularization parameter λ
634 minimising mean cross-validated error, and yielding the features in the table above. In a logistic model regressing
635 EPC on these features, significant predictors of EPC included: chronic kidney disease, obesity (BMI>30), and
636 RNAemia. RNAemia was associated with 2.8 times the odds of EPC, comparable in magnitude to the association
637 between obesity and development of EPC. Mean cross-validated area under the receiver-operating characteristic
638 curve (AUROC) of the model in predicting EPC was 0.73.
639

640 **References**

- 641
- 642 1 WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int> (accessed Dec
643 17, 2020).
- 644 2 Gupta A, Madhavan MV, Sehgal K, *et al.* Extrapulmonary manifestations of COVID-19. *Nat*
645 *Med* 2020; **26**: 1017–32.
- 646 3 Zheng KI, Feng G, Liu W-Y, Targher G, Byrne CD, Zheng M-H. Extrapulmonary
647 complications of COVID-19: A multisystem disease? *J Med Virol* 2020; published online July
648 10. DOI:10.1002/jmv.26294.
- 649 4 Zhang W, Du R-H, Li B, *et al.* Molecular and serological investigation of 2019-nCoV infected
650 patients: implication of multiple shedding routes. *Emerging Microbes & Infections* 2020; **9**:
651 386–9.
- 652 5 Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in Different Types of Clinical
653 Specimens. *JAMA* 2020; **323**: 1843–4.
- 654 6 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients
655 with COVID-2019. *Nature* 2020; **581**: 465–9.
- 656 7 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel
657 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 658 8 Bermejo-Martin JF, González-Rivera M, Almansa R, *et al.* Viral RNA load in plasma is
659 associated with critical illness and a dysregulated host response in COVID-19. *Infectious*
660 *Diseases (except HIV/AIDS)*, 2020 DOI:10.1101/2020.08.25.20154252.
- 661 9 Veyer D, Kernéis S, Poulet G, *et al.* Highly sensitive quantification of plasma SARS-CoV-2
662 RNA sheds light on its potential clinical value. *Clinical Infectious Diseases* 2020; : ciaa1196.
- 663 10The Massachusetts Consortium for Pathogen Readiness, Fajnzylber J, Regan J, *et al.* SARS-
664 CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun*
665 2020; **11**: 5493.
- 666 11Tavazzi G, Pellegrini C, Maurelli M, *et al.* Myocardial localization of coronavirus in COVID-
667 19 cardiogenic shock. *Eur J Heart Fail* 2020; **22**: 911–5.
- 668 12Puelles VG, Lütgehetmann M, Lindenmeyer MT, *et al.* Multiorgan and Renal Tropism of
669 SARS-CoV-2. *N Engl J Med* 2020; **383**: 590–2.
- 670 13Su H, Yang M, Wan C, *et al.* Renal histopathological analysis of 26 postmortem findings of
671 patients with COVID-19 in China. *Kidney International* 2020; **98**: 219–27.
- 672 14Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of
673 SARS-CoV-2. *Gastroenterology* 2020; **158**: 1831-1833.e3.

- 674 15Zheng S, Fan J, Yu F, *et al.* Viral load dynamics and disease severity in patients infected with
675 SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.
676 *BMJ* 2020; **369**: m1443.
- 677 16Chan JF-W, Yuan S, Kok K-H, *et al.* A familial cluster of pneumonia associated with the
678 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.
679 *Lancet* 2020; **395**: 514–23.
- 680 17Hogan CA, Stevens BA, Sahoo MK, *et al.* High Frequency of SARS-CoV-2 RNAemia and
681 Association With Severe Disease. *Clinical Infectious Diseases* 2020; ciaa1054.
- 682 18Dahdouh E, Lázaro-Perona F, Romero-Gómez MP, Mingorance J, García-Rodríguez J. Ct
683 values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of
684 viral load. *Journal of Infection* 2020; S0163445320306757.
- 685 19Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular
686 diagnostic tool. *Clin Chem* 2015; **61**: 79–88.
- 687 20WHO Working Group on the Clinical Characterisation and Management of COVID-19
688 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet*
689 *Infect Dis* 2020; **20**: e192–7.
- 690 21Cornfield J. A statistical problem arising from retrospective studies. University of California
691 Press Berkeley, CA, 1956: 135–48.
- 692 22Kuypers J, Jerome KR. Applications of Digital PCR for Clinical Microbiology. *J Clin*
693 *Microbiol* 2017; **55**: 1621–8.
- 694 23Eberhardt KA, Meyer-Schwickerath C, Heger E, *et al.* RNAemia Corresponds to Disease
695 Severity and Antibody Response in Hospitalized COVID-19 Patients. *Viruses* 2020; **12**.
696 DOI:10.3390/v12091045.
- 697 24Xu D, Zhou F, Sun W, *et al.* Relationship Between serum SARS-CoV-2 nucleic
698 acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study. *Clin Infect Dis*
699 2020; published online July 28. DOI:10.1093/cid/ciaa1085.
- 700 25Järhult JD, Hultström M, Bergqvist A, Frithiof R, Lipcsey M. The Impact of Viremia on
701 Organ Failure, Biomarkers and Mortality in a Swedish Cohort of Critically ill COVID-19
702 Patients. In Review, 2020 DOI:10.21203/rs.3.rs-115082/v1.
- 703 26Ai T, Yang Z, Hou H, *et al.* Correlation of Chest CT and RT-PCR Testing for Coronavirus
704 Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020; **296**: E32–40.
- 705 27Prebensen C, Myhre PL, Jonassen C, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2
706 RNA in Plasma Is Associated With Intensive Care Unit Admission and Mortality in Patients
707 Hospitalized With Coronavirus Disease 2019. *Clinical Infectious Diseases* 2020; : ciaa1338.

- 708 28Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution
709 of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding
710 SARS pathogenesis. *J Pathol* 2004; **203**: 631–7.
- 711 29Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new
712 potential mechanism of heart injury among patients infected with SARS-CoV-2.
713 *Cardiovascular Research* 2020; **116**: 1097–100.
- 714 30Andersson M, Arancibia - Carcamo CV, Auckland K, *et al.* SARS-CoV-2 RNA detected in
715 blood samples from patients with COVID-19 is not associated with infectious virus. *Infectious*
716 *Diseases (except HIV/AIDS)*, 2020 DOI:10.1101/2020.05.21.20105486.
- 717 31Gu J, Gong E, Zhang B, *et al.* Multiple organ infection and the pathogenesis of SARS.
718 *Journal of Experimental Medicine* 2005; **202**: 415–24.
- 719 32Law HKW, Cheung CY, Ng HY, *et al.* Chemokine up-regulation in SARS-coronavirus–
720 infected, monocyte-derived human dendritic cells. *Blood* 2005; **106**: 2366–74.
- 721 33Li L, Wo J, Shao J, *et al.* SARS-coronavirus replicates in mononuclear cells of peripheral
722 blood (PBMCs) from SARS patients. *Journal of Clinical Virology* 2003; **28**: 239–44.
- 723 34Goyal A, Cardozo-Ojeda EF, Schiffer JT. Potency and timing of antiviral therapy as
724 determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.
725 *Sci Adv* 2020; **6**: eabc7112.
- 726